Mesothelin family proteins and diagnosis of mesothelioma: Analytical evaluation of an automated immunoassay and preliminary clinical results

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 5, 2007, Pages 634-638

  Di Serio, Francesca ^a   Fontana, Antonietta ^a   Loizzi, Michele ^a   Capotorto, Giuseppe ^a   Maggiolini, Piera ^a   Mera, Ernesto ^a   Bisceglia, Lucia ^a   Molinini, Raffaele ^a  

^a POLICLINICO   (Italy)

Author keywords

Mesothelioma; Soluble mesothelin related peptides

Indexed keywords

ASBESTOS; MESOTHELIN;

ADULT; ANALYTIC METHOD; ARTICLE; ASBESTOSIS; AUTOANALYZER; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA DISEASE; PLEURA MESOTHELIOMA; PLEURA PLAQUE; PRIORITY JOURNAL;

AGED; AUTOMATION; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34248209656     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.112     Document Type: Article

References (15)

1. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-8.
2. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17.
3. Scholler N, Fu N, Yang Y, Ye Z, Goodman Ge, Hellstrom He, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96:11531-6.
4. Robinson BW, Creaney J, Lake R, Novak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
5. Robinson BW, Creaney J, Lake R, Novak A, Musk AW, de Klerk N, et al. Soluble mesothelin-related protein. A blood test for mesothelioma. Lung Cancer 2005;49(Suppl 1):S109-11.
6. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
7. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS guideline EP5-A. Wayne, PA: NCCLS, 1999.
8. National Committee for Clinical Laboratory Standards. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; proposed guideline. NCCLS guideline EP6-A. Wayne, PA: NCCLS, 1986.
9. National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry: proposed guideline. NCCLS guideline EP7-P. Wayne, PA: NCCLS, 1986.
10. American Thoracic Society. Diagnosis and initial management of non-malignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691-715.
11. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:11228.
12. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
13. Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O. Tissue polypeptide antigen (TPA) hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 2003;23:531-6.
14. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001;92:1224-30.
15. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.